2020 American Transplant Congress
Direct Acting Anti-Viral Prophylaxis to Prevent Virus Transmission from Hepatitis C Viremic Donors to Hepatitis C Negative Kideney Transplant Recipients
Virginia Commonwealth University, Richmond, VA
*Purpose: Previous trials in kidney transplantation (KT) have described a 12-week course of direct-acting anti-viral drugs (DAA) to treat HCV transmission from infected donors to…2020 American Transplant Congress
Multi-Center, Open-Label Trial of Pre-Emptive Glecaprevir/Pibrentasvir (G/P) to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus (MYTHIC)
*Purpose: Kidneys from Hepatitis C virus (HCV)-infected deceased donors continue to be discarded at high rates despite small, successful studies of HCV-viremic donors into uninfected…2020 American Transplant Congress
Utilization of Hepatitis C Positive Organs in Kidney Transplantation
Ochsner Medical Center, New Orleans, LA
*Purpose: The efficacy of direct acting antivirals (DAAs) in HCV has cleared the path for the use of HCV positive donor kidneys into negative recipients.…2020 American Transplant Congress
Solid Organ Transplantation Using Hepatitis C Virus Positive Donor Organs for Hepatitis C Virus Negative Recipients
New York Medical College/ Westchester Medical Center, Valhalla, NY
*Purpose: To determine the effects of transplanting an HCV-positive solid organ to an uninfected patient who is on the transplant waiting list and might otherwise…2020 American Transplant Congress
Longer-Term Outcomes from the THINKER and EXPANDER Trials of Transplantation Using HCV-Viremic Kidneys
*Purpose: The practice of transplanting HCV-viremic kidneys into HCV-negative recipients has become more common, but longer-term outcomes have not been reported. We present data on…2020 American Transplant Congress
Utilization of Hepatitis C Viremic Donors in Liver Transplantation. A Single Center Experience
*Purpose: The evolution of effective direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV), in the setting of the well recognized organ shortage and the…2020 American Transplant Congress
Glecaprevir-Pibrentasvir Effect on Tacrolimus Troughs in Abdominal Transplant Recipients
The Ohio State Wexner Medical Center, Columbus, OH
*Purpose: Glecaprevir-pibrentasvir (GP) is one of several pangenotypic therapies available for the treatment of hepatitis C. Historical use of ritonavir based hepatitis C therapies increased…2020 American Transplant Congress
Pharmacy Led Initiatives for Treatment of Transplant Recipients of Hepatitis C Viremic Donors in a High Volume Transplant Center
Duke University Medical Center, Durham, NC
*Purpose: We describe a multidisciplinary workflow for initiation of hepatitis C virus (HCV) direct-acting antiviral (DAA) therapies post-transplant in the outpatient setting of a high…2020 American Transplant Congress
Adult Primary Liver Transplant Recipient Outcomes by Immunosuppression Induction Received
*Purpose: It has long been recognized that the highest risk of rejection of an organ is in the first few months post transplantation. To prevent…2020 American Transplant Congress
Waitlist Times, Hospital Length of Stay, and Immediate Post-Operative Outcomes of HCV Positive Donors in HCV Negative Liver and Kidney Transplant Recipients
*Purpose:Introduction The advent of direct-acting antivirals (DAAs) has significantly changed liver and kidney transplantation for patients with chronic hepatitis C (HCV) infection. Successful and relatively…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 28
- Next Page »